Abstract
An α1a – and α1d – adrenergic receptor (AR) selective antagonist may be a more efficacious treatment for BPH/LUTS patients and may have fewer side effects than the existing pharmaceuticals. A facile synthesis for a series of (2-cyclopropoxyphenyl)piperidine derivatives has been developed, in which aryl vinyl ether formation and subsequent cyclopropyl formation provide efficient access to key intermediate N-Boc-4-(2-cyclopropoxyphenyl)piperidine. The synthesized (2-cyclopropoxyphenyl)piperidine derivatives display high affinity and selectivity for α1a – AR and α1d – AR compared to α1b-AR and D2 receptor, Ki values for α1a-AR are 0.91 nM to 79.0 nM and α1d-AR are 2.0 nM to 57 nM; Ki values for α1b-AR are 107 nM to 839.8 nM and D2 receptor are 66.2 nM to 187.1 nM. The selectivity ratios of Ki(α1b)/Ki(α1a) are 11 to 155 fold, Ki(α1b)/Ki(α1d) are 6 to 171 fold, Ki(D2)/Ki(α1a) are 2 to 158 fold, and Ki(D2)/Ki(α1d) are 1.2 to 89 fold. Compound 17a shows improved stability in human liver microsome test (t1/2 = 18 minutes).
Keywords: Synthesis, piperidine Derivatives, Receptor Inhibitors, microsome test, 8-methoxyfluoroquinolone
Medicinal Chemistry
Title: Synthesis, In Vitro Activities of (2-Cyclopropoxyphenyl)piperidine Derivatives for α1a and α1d Adrenergic Receptor Inhibitors
Volume: 5 Issue: 1
Author(s): Shengjian Li, George Chiu, Virginia L. Pulito, Jingchun Liu, Peter J. Connolly and Steven A. Middleton
Affiliation:
Keywords: Synthesis, piperidine Derivatives, Receptor Inhibitors, microsome test, 8-methoxyfluoroquinolone
Abstract: An α1a – and α1d – adrenergic receptor (AR) selective antagonist may be a more efficacious treatment for BPH/LUTS patients and may have fewer side effects than the existing pharmaceuticals. A facile synthesis for a series of (2-cyclopropoxyphenyl)piperidine derivatives has been developed, in which aryl vinyl ether formation and subsequent cyclopropyl formation provide efficient access to key intermediate N-Boc-4-(2-cyclopropoxyphenyl)piperidine. The synthesized (2-cyclopropoxyphenyl)piperidine derivatives display high affinity and selectivity for α1a – AR and α1d – AR compared to α1b-AR and D2 receptor, Ki values for α1a-AR are 0.91 nM to 79.0 nM and α1d-AR are 2.0 nM to 57 nM; Ki values for α1b-AR are 107 nM to 839.8 nM and D2 receptor are 66.2 nM to 187.1 nM. The selectivity ratios of Ki(α1b)/Ki(α1a) are 11 to 155 fold, Ki(α1b)/Ki(α1d) are 6 to 171 fold, Ki(D2)/Ki(α1a) are 2 to 158 fold, and Ki(D2)/Ki(α1d) are 1.2 to 89 fold. Compound 17a shows improved stability in human liver microsome test (t1/2 = 18 minutes).
Export Options
About this article
Cite this article as:
Li Shengjian, Chiu George, Pulito L. Virginia, Liu Jingchun, Connolly J. Peter and Middleton A. Steven, Synthesis, In Vitro Activities of (2-Cyclopropoxyphenyl)piperidine Derivatives for α1a and α1d Adrenergic Receptor Inhibitors, Medicinal Chemistry 2009; 5 (1) . https://dx.doi.org/10.2174/157340609787049280
DOI https://dx.doi.org/10.2174/157340609787049280 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Hybrid Molecules Synergistically Acting Against Protein Aggregation Diseases
Current Topics in Medicinal Chemistry Cell Biological Manifestations of Bisdioxopiperazines: Treatment of Human Tumor Cell Lines in Culture
Anti-Cancer Agents in Medicinal Chemistry Thematic Analysis™ : A Chemogenomic Approach to GPCR Drug Discovery
Current Topics in Medicinal Chemistry Towards an Experimental and Systems Biology Framework for Cancer Cell Therapeutics
Current Bioinformatics Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis
Current Neurovascular Research Role of Open Source Tools and Resources in Virtual Screening for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Prospective Clinical Role for Anticancer Garlic Organosulfur Compounds (Guest Editor: Hassan T. Hassan)]
Anti-Cancer Agents in Medicinal Chemistry Mechanism-Based Treatment in Chronic Neuropathic Pain: The Role of Antidepressants
Current Pharmaceutical Design Oxidative Stress Based-Biomarkers in Oral Carcinogenesis: How Far Have We Gone?
Current Molecular Medicine Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]
Current Pharmaceutical Design PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Monoclonal Antibodies in the Management of Solid Tumors
Current Topics in Medicinal Chemistry A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design Synthetic Methods of Disulfide Bonds Applied in Drug Delivery Systems
Current Organic Chemistry Melatonin Therapy of Pediatric Sleep Disorders: Recent Advances, Why it Works, Who are the Candidates and How to Treat
Current Pediatric Reviews Green Reduction of Graphene Oxide into Graphene by Cow Urine
Current Nanomaterials